Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.

BACKGROUND & AIMS Peutz-Jeghers syndrome (PJS) is typically manifested as severe gastrointestinal polyposis. Polyps in PJS patients and in Lkb1(+/-) mice that model PJS polyposis are frequently characterized by elevated cyclooxygenase-2 (COX-2). This study was designed to determine whether COX-2 inhibition would reduce tumor burden in Lkb1(+/-) mice or Peutz-Jeghers patients. METHODS Genetic interactions between Cox-2 and Lkb1 in polyp formation were analyzed in mice with combined deficiencies in these genes. Pharmacologic inhibition of COX-2 was achieved by supplementing the diet of Lkb1(+/-) mice with 1500 ppm celecoxib between 3.5-10 and 6.5-10 months. In PJS patients, COX-2 was inhibited with a daily dose of 2 x 200 mg celecoxib for 6 months. RESULTS Total polyp burden in Lkb1(+/-) mice was significantly reduced in a Cox-2(+/-) (53%) and in a Cox-2(-/-) (54%) background. Celecoxib treatment initiating before polyposis (3.5-10 months) led to a dramatic reduction in tumor burden (86%) and was associated with decreased vascularity of the polyps. Late treatment (6.5-10 months) also led to a significant reduction in large polyps. In a pilot clinical study, a subset of PJS patients (2/6) responded favorably to celecoxib with reduced gastric polyposis. CONCLUSIONS These data establish a role for COX-2 in promoting Peutz-Jeghers polyposis and suggest that COX-2 chemoprevention may prove beneficial in the treatment of PJS.

[1]  Jérôme Boudeau,et al.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1 , 2004, The EMBO journal.

[2]  Hans C Clevers,et al.  Complete Polarization of Single Intestinal Epithelial Cells upon Activation of LKB1 by STRAD , 2004, Cell.

[3]  M. Taketo,et al.  Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas , 2004, British Journal of Cancer.

[4]  J. J. Sung,et al.  Chemoprevention of gastric cancer by celecoxib in rats , 2004, Gut.

[5]  H. S. Kim,et al.  Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. , 2004, European journal of cancer.

[6]  A. Spigelman,et al.  Preventive measures in Peutz-Jeghers syndrome , 2004, Familial Cancer.

[7]  C. Amos,et al.  Correlation of Staining for LKB1 and COX-2 in Hamartomatous Polyps and Carcinomas from Patients with Peutz–Jeghers Syndrome , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[9]  M. Taketo,et al.  Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. , 2003, Cancer research.

[10]  S. Gruber,et al.  Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  R. Houlston,et al.  Further observations on LKB1/STK11 status and cancer risk in Peutz–Jeghers syndrome , 2003, British Journal of Cancer.

[12]  E. Montgomery,et al.  Loss of Stk11/Lkb1 Expression in Pancreatic and Biliary Neoplasms , 2003, Modern Pathology.

[13]  Claus Belka,et al.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Daniel St Johnston,et al.  A role for Drosophila LKB1 in anterior–posterior axis formation and epithelial polarity , 2003, Nature.

[15]  R. Yamazaki,et al.  Selective cyclooxygenase‐2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells , 2002, FEBS letters.

[16]  J. Deeks,et al.  Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials , 2002, BMJ : British Medical Journal.

[17]  Ronald A. DePinho,et al.  Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation , 2002, Nature.

[18]  L. Aaltonen,et al.  Induction of cyclooxygenase-2 in a mouse model of Peutz–Jeghers polyposis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Seldin,et al.  Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. , 2002, Cancer research.

[20]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[21]  K. Jishage,et al.  Role of Lkb1, the causative gene of Peutz–Jegher's syndrome, in embryogenesis and polyposis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.

[23]  Hiroyuki Miyoshi,et al.  Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. , 2002, Cancer research.

[24]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[25]  S. Narumiya,et al.  Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in ApcΔ716 mouse intestinal polyps , 2002 .

[26]  S. Grösch,et al.  COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[28]  K. Alitalo,et al.  Vascular Abnormalities and Deregulation of VEGF in Lkb1-Deficient Mice , 2001, Science.

[29]  J. Keller,et al.  Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome , 2001, Journal of clinical pathology.

[30]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[31]  M. Stolte,et al.  Gastric polyps: an update of their pathology and biological significance , 2000, Virchows Archiv.

[32]  T. Iwama,et al.  Somatic mutations of LKB1 and beta-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome. , 2000, Cancer research.

[33]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[34]  T. Mäkelä,et al.  Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Boor,et al.  Peutz-Jeghers syndrome: 78-year follow-up of the original family , 1999, The Lancet.

[36]  M. Polymeropoulos,et al.  Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. , 1998, Cancer research.

[37]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[38]  R. Houlston,et al.  Peutz-Jeghers syndrome. , 1997, Journal of medical genetics.

[39]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[40]  J. Johnston,et al.  Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II , 1995, Nature.

[41]  P. Fisher,et al.  Cell cycle arrest. , 1995, Science.

[42]  Charles E. Kahn,et al.  Peutz-Jeghers syndrome , 1995 .